Serotype distribution of Streptococcus pneumoniae in children with invasive diseases in Turkey: 2008-2014

Basit Öğe Kaydı
dc.contributor.authorCeyhan, Mehmet
dc.contributor.authorOzsurekci, Yasemin
dc.contributor.authorGurler, Nezahat
dc.contributor.authorOksuz, Lutfiye
dc.contributor.authorAydemir, Sohret
dc.contributor.authorOzkan, Sengul
dc.contributor.authorYuksekkaya, Serife
dc.date.accessioned2020-03-26T19:26:16Z
dc.date.available2020-03-26T19:26:16Z
dc.date.issued2016
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractSuccessful vaccination policies for protection from invasive pneumococcal diseases (IPD) dependent on determination of the exact serotype distribution in each country. We aimed to identify serotypes of pneumococcal strains causing IPD in children in Turkey and emphasize the change in the serotypes before and after vaccination with 7-valent pneumococcal conjugate vaccine (PCV-7) was included and PCV-13 was newly changed in Turkish National Immunization Program. Streptococcus pneumoniae strains were isolated at 22 different hospitals of Turkey, which provide healthcare services to approximately 65% of the Turkish population. Of the 335 diagnosed cases with S. pneumoniae over the whole period of 2008-2014, the most common vaccine serotypes were 19F (15.8%), 6B (5.9%), 14 (5.9%), and 3 (5.9%). During the first 5y of age, which is the target population for vaccination, the potential serotype coverage ranged from 57.5 % to 36.8%, from 65.0% to 44.7%, and from 77.4% to 60.5% for PCV-7, PCV-10, and PCV-13 in 2008-2014, respectively. The ratio of non-vaccine serotypes was 27.2% in 2008-2010 whereas was 37.6% in 2011-2014 (p=0.045). S. penumoniae serotypes was less non-susceptible to penicillin as compared to our previous results (33.7vs 16.5 %, p=0.001). The reduction of those serotype coverage in years may be attributed to increasing vaccinated children in Turkey and the increasing non-vaccine serotype may be explained by serotype replacement. Our ongoing IPD surveillance is a significant source of information for the decision-making processes on pneumococcal vaccination.en_US
dc.description.sponsorshipPfizerPfizeren_US
dc.description.sponsorshipThis study was supported by Pfizer.en_US
dc.identifier.doi10.1080/21645515.2015.1078952en_US
dc.identifier.endpage313en_US
dc.identifier.issn2164-5515en_US
dc.identifier.issn2164-554Xen_US
dc.identifier.issue2en_US
dc.identifier.pmid26325175en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage308en_US
dc.identifier.urihttps://dx.doi.org/10.1080/21645515.2015.1078952
dc.identifier.urihttps://hdl.handle.net/20.500.12395/33979
dc.identifier.volume12en_US
dc.identifier.wosWOS:000371745700019en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS INCen_US
dc.relation.ispartofHUMAN VACCINES & IMMUNOTHERAPEUTICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectepidemiologyen_US
dc.subjectserotypesen_US
dc.subjectS. pneumoniaeen_US
dc.subjectsurveillanceen_US
dc.subjectTurkeyen_US
dc.titleSerotype distribution of Streptococcus pneumoniae in children with invasive diseases in Turkey: 2008-2014en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu